

D6.5 / Midterm report on project visibility and educational material

Editor	Contractual delivery date	Actual delivery date
Kristina Leipuviene (SMARTSOL SIA)	August 2025	August 2025
Deliverable type	Dissemination level	Version - date
R - Document, report	PU – Public	1.0 - 29/08/2025



Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency. Neither the European Union nor the European Health and Digital Executive Agency can be held responsible for them.

Deliverable ID

Project acronym	iPROLEPSIS
Project full title	Psoriatic arthritis inflammation explained through multi-source data analysis guiding a novel personalised digital care ecosystem
Grant Agreement ID	101095697
Deliverable number	D6.5
Deliverable title	Midterm report on project visibility and educational material
Work package	WP6 - Dissemination, communication and exploitation
Deliverable type	R - Document, report
Dissemination level	PU – Public
Version - date	1.0 - 29/08/2025
Contractual delivery date	August 2025
Actual delivery date	August 2025
Lead partner	SMARTSOL SIA
Editor	Kristina Leipuviene (SMARTSOL SIA)
Contributors	Amalia Ntemou (INTRA); Cátia Goncalves (SPR); Patty de Groot (EMC)
Reviewed by	Ioannis Drivas (DBC) Silvia Reis (PLUX)
Approved by	Leontios Hadjileontiadis (AUTH, Project Coordinator)
Keywords	Communication; Clustering; Dissemination; Educational material; Networking; Visibility

Document history

Version	Date	Contributors	Action / status
0.1	05/06/2025	SMARTSOL SIA	Document structure (table of contents) ready
0.2	10/07/2025	SMARTSOL SIA	1st draft ready
0.3	23/07/2025	SPR, INTRA	Revised sections 2.8 PsA educational material and 2.9 Clustering and networking activities. Ready for internal review
0.4	02/08/2025	AUTH	Ready for internal review
0.4	02/08/2025	DBC	Reviewed by Ioannis Drivas (DBC)
0.4	13/08/2025	PLUX	Reviewed by Silvia Reis (PLUX)
0.5	20/08/2025	SMARTSOL SIA	Document revised
1.0	29/08/2025	-	Approved by the Project Coordinator
1.0	31/08/2025	-	Submitted to the EC by the Project Coordinator

Contents

List of figures.....	6
List of tables.....	7
List of abbreviations.....	8
Executive summary.....	9
1 Introduction	10
1.1 Document scope	10
1.2 Document structure	11
2 Report on project visibility and educational material.....	11
2.1 Dissemination and communication approach.....	11
2.2 Target audience	12
2.3 Project identity (visual and branding)	12
2.4 Media.....	12
2.4.1 Website.....	13
2.4.2 Social media	14
2.4.3 Partners involvement in online visibility	20
2.4.4 Newsletter.....	20
2.4.5 Major media.....	22
2.5 Publications	23
2.5.1 Scientific publications	23
2.5.2 Publications in business magazines	24
2.6 Events.....	25
2.6.1 Scientific conferences	26
2.6.2 Business and industry events	30
2.6.3 Workshops, seminars and special sessions	32
2.6.4 Clinical focus groups with patients.....	35
2.7 Communication material	36
2.8 PsA educational material	37
2.9 Clustering and networking activities	39
2.9.1 Booster service delivery	39
2.9.2 Collaboration with EU initiatives and networking activities.....	41
3 Communication and dissemination KPIs.....	42
4 Conclusions.....	45

List of figures

Figure 1 Updated website with new sections – Learning Hub, Deliverables, Publications and Apps for Download.....	13
Figure 2 Website page views 2023 06 01 – 2025 07 01	14
Figure 3 iPROLEPSIS number of followers on social media channels	15
Figure 4 iPROLEPSIS LinkedIn profile and followers demographics	16
Figure 5 iPROLEPSIS presence LinkedIn.....	16
Figure 6 iPROLEPSIS Instagram profile	17
Figure 7 iPROLEPSIS X profile	18
Figure 8 X Communities joined by iPROLEPSIS for thematic digital health engagement	18
Figure 9 iPROLEPSIS Facebook profile.....	19
Figure 10 iPROLEPSIS Bluesky profile.....	19
Figure 11 iPROLEPSIS YouTube profile.....	20
Figure 12 Examples of iPROLEPSIS partner's dissemination activities on social media	21
Figure 13 iPROLEPSIS Newsletters	21
Figure 14 iPROLEPSIS Newsletter on Zenodo.....	22
Figure 15 Digital Rheumatology Network Podcast on Spotify	23
Figure 16 Article in the Psoriasispatiënten Nederland Psoriasis Magazine	25
Figure 17 Grappa Annual Meeting 2025	26
Figure 18 The 7th Panhellenic Multidisciplinary Congress of Autoimmune Diseases, Rheumatology & Clinical Immunology.....	27
Figure 19 Health Data Summit 2025	27
Figure 20 The 2nd Healthy Longevity Symposium	28
Figure 21 The 11th International Conference on Software Development and Technologies for Enhancing Accessibility and Fighting Info-exclusion (DSAI 2024)	28
Figure 22 The 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)	29
Figure 23 IEEE MELECON 2024.....	30
Figure 24 Final pitch session of the HiTech Program	31
Figure 25 InnoHealth Forum 2024.....	32
Figure 26 The 1st Morning Health Talk – Greece	33
Figure 27 Workshops at Health Data Summit 2025	33
Figure 28 The Pitch Competition during the PhD Open Days	34
Figure 29 Informative event for World Psoriasis Day 2024 in Nijkerk (the Netherlands)	34
Figure 30 The European Researchers' Night.....	34
Figure 31 The HUMAN Lab meetup	35
Figure 32 iPROLEPSIS flyer, poster and roll-up displayed at events.....	37
Figure 33 Preview of the upgraded Learning Hub page on the iPROLEPSIS website	38
Figure 34 Social media campaign introducing the cluster	40
Figure 35 iPROLEPSIS presented at the COMFORT-EU project plenary meeting	41

List of tables

Table 1 Social media channels	14
Table 2 Number of interactions with patients.....	35
Table 3 Patient participation by format	36
Table 4 Target and reached KPIs for M1-M18	43

List of abbreviations

AI	Artificial Intelligence
DHTs	Digital Health Tools
DoA	Description of Action
EU	European Union
GDPR	General Data Protection Regulation
HCPs	Healthcare Professionals
HRB	Horizon Results Booster
KPIs	Key Performance Indicators
PsA	Psoriatic Arthritis
PsO	Psoriasis
R&I	Research and Innovation
WP	Work Package

Executive summary

This document is Deliverable D6.5, “Midterm report on project visibility and educational material.” It provides an overview of the dissemination, communication, networking, and educational content development activities carried out by the iPROLEPSIS consortium during the period from M19 to M32. The report builds on the foundations established during the first reporting phase (M1-M18) and reflects the consortium’s ongoing efforts to raise visibility, engage stakeholders, and support the broader uptake of project results.

Communication and dissemination activities continued across multiple channels, including the project website, newsletters, social media, and participation in scientific and business events. Scientific publication output increased significantly during this period, reaching a total of 10 publications, five of which are peer-reviewed, with several additional manuscripts under preparation or review. In parallel, outreach materials such as video interviews, short videos, and infographics were developed and disseminated to support stakeholder engagement and increase awareness of psoriatic arthritis (PsA).

The project also made notable progress in educational content development. The Psoriatic Arthritis Patient Handbook and a set of 18 infographics have been finalised and published in English, with translations into Dutch, Greek, and Portuguese completed and ready for release. A redesigned version of the Learning Hub is under development, with integration into the miPROLEPSIS mobile application planned for the next phase.

Networking and collaboration activities were expanded through the establishment of a formal cluster with AI-PROGNOSIS and REBECCA EU projects, supported by Horizon Results Booster services. The consortium participated in a total of seven networking and joint dissemination initiatives, including a joint session at the Health Data Summit 2025 and the co-organisation of an upcoming workshop at IEEE HealthCom 2025 conference.

Dissemination and communication progress has been monitored throughout the reporting period using the project’s defined KPIs. Several targets have been reached or closely approached, including those related to event participation and networking. Other metrics, such as newsletter subscriptions and social media growth, continue to show steady progress. Although the number of monthly website visitors remains below the long-term target, upgrades to the Learning Hub and its future integration into the app are expected to enhance accessibility and increase engagement.

This deliverable contributes to Work Package 6 (WP6) and supports the objectives set out in earlier deliverables, including D6.2, D6.3, and D6.8. It is associated with the implementation of Tasks T6.1 (Dissemination and communication planning, implementation and monitoring), T6.2 (Clustering and networking activities), and T6.3 (PsA educational content development). It is also closely connected to Work Package 2 (WP2), particularly Task 2.2, which focuses on user research and co-creation process and implementation.

The next and final reporting on project visibility and educational material will be presented in Deliverable D6.6, scheduled for M48.

1 Introduction

This document is D6.5, “Midterm report on project visibility and educational material” within the iPROLEPSIS project. It presents a detailed overview of dissemination, communication, clustering, and educational content development carried out by the consortium during the M19–M32 period.

Building on the foundations established in the first reporting period (M1–M18), the project has continued to advance its efforts to engage target audiences, raise awareness about psoriatic arthritis (PsA), and increase visibility through strategic communication channels. This report highlights the implementation of the dissemination and communication plan, the creation of PsA-related educational content, and the clustering and networking efforts. Progress is measured using the project’s Key Performance Indicators (KPIs).

This deliverable is part of WP6, “Dissemination, communication and exploitation”, and builds on earlier deliverables, particularly D6.2, “Dissemination, Exploitation, and Communication Plan” and D6.3, “First report on project visibility and educational material”. It also aligns with strategic updates included in D6.8, “Update on the Dissemination, Exploitation, and Communication Plan”, which reflect refinements to the overall approach and integration of feedback and evolving needs.

1.1 Document scope

Deliverable D6.5 covers the period from M19 (July 2024) to M32 (August 2025) and serves as the midterm report under WP6. It focuses on the implementation and progress of visibility measures, communication efforts, clustering and networking activities, and the development of educational content related to PsA.

The deliverable addresses the following WP6 tasks:

- T6.1, “Dissemination and communication planning, implementation and monitoring”
- T6.2, “Clustering and networking activities”, and
- T6.3, “PsA educational content development”.

It is also linked with the work carried out in WP2, specifically Task 2.2, which was responsible for organising and conducting the clinical focus groups and co-creation sessions reported in this deliverable.

This report includes:

- Summary of outreach activities through the website, social media, newsletters, and participation in conferences, workshops, and other events
- Overview of scientific and business publications
- Progress on the development of educational content focused on PsA
- Engagement in joint activities with related EU-funded initiatives and other stakeholders’ involvement initiatives, and
- Evaluation of progress against KPIs defined in the Description of Action (DoA).

This deliverable complements D6.3 and feeds into the final reporting that will be delivered through D6.6, “Final report on project visibility and educational material” scheduled for the end of the project (M48).

1.2 Document structure

This document provides an overall view of dissemination, communication, networking activities, and educational material developed within the iPROLEPSIS project up to M32. The sections included are as follows:

- **Executive Summary** provides a summary of the entire document, highlighting key achievements and takeaways from the reporting period.
- **Section 1** introduces the scope of the report, focusing on project visibility and educational content.
- **Section 2** encompasses various aspects, including the dissemination and communication approach, target audiences, use of project identity and branding, use of media platforms for outreach (website, social media, newsletter, and major media), dissemination of results through scientific and business publications, participation in visibility-related events, creation of PsA educational content, and engagement in clustering and networking activities.
- **Section 3** includes evaluation of dissemination and communication performance based on the project's KPIs.
- **Section 4** provides a summary of the main findings and conclusions drawn from the reporting period and outlines next steps for the final project phase.

2 Report on project visibility and educational material

2.1 Dissemination and communication approach

The iPROLEPSIS dissemination and communication approach is intended to be dynamic and adaptable, evolving alongside project developments and stakeholder needs. The full strategic framework was established in D6.2 and later refined D6.8, where a structured three-phase dissemination model was introduced to guide the project's outreach over time.

The three phases are as follows:

- **Phase 1:** Awareness and Community Building (M1–M18) – Focused on establishing communication foundations, launching the project's branding, and initiating stakeholder engagement.
- **Phase 2:** Active Dissemination and Engagement (M18–M36) – Currently ongoing, this phase emphasises the expansion of scientific and public visibility, development of educational content, and deepening of collaboration through joint dissemination actions.
- **Phase 3:** Sustainability and Long-Term Impact (M36–M48) – Will focus on publishing final project results with open access, strengthening clustering and networking activities, promoting PsA educational content, and supporting Open Science principles to ensure accessibility and transparency.

This phased approach helps ensure that dissemination efforts remain aligned with key project milestones and can adapt to new opportunities or feedback.

A detailed description of the dissemination and communication strategy, including tools, audiences, and responsibilities, is available in D6.2 and D6.8.

2.2 Target audience

The classification of target audiences for iPROLEPSIS dissemination and communication activities remains consistent with the definitions outlined in D6.2 and reaffirmed in D6.8. These audiences include:

- **Research community** – Biologists, biochemists, pharmacists, AI scientists, and engineers.
- **Clinical community** – Rheumatologists, dermatologists, primary care providers, cardiologists, and physical/occupational therapists.
- **Biomedical technology and pharmaceutical industry** – Companies involved in medical innovation and commercial application.
- **Patients and their associations** – Individuals living with or at risk of PsA, as well as caregivers and patient advocacy groups.
- **Policymakers** – Government authorities, regulators, and decision-makers influencing healthcare policies and digital health adoption.
- **General public** – Broader audiences, including those interested in health technologies and patient-centered research.

Engagement with these groups is pursued through scientific publications, conference presentations, focus groups, workshops, industry events, and digital communication via the project website, social media, and newsletters.

A detailed description of the main target groups and associated communication methods is available in D6.2 and D6.8.

2.3 Project identity (visual and branding)

The visual identity and branding of iPROLEPSIS were established at the beginning of the project and remain unchanged during the current reporting period (M19–M32). The project's logo, colour palette, animated logo video, and communication templates were developed to ensure a unified and recognisable identity across all dissemination and communication materials and channels.

These branding elements are described in detail D6.1, “Project branding and communication channels”, which outlines the development of the visual materials and social media guidelines. D6.3 also presents the visual identity components introduced earlier in the project. As no updates were made during this reporting period, the original branding remains fully applicable.

All visual identity assets continue to be used consistently and remain accessible to consortium partners via the internal repository and the project website, in the “Knowledge base” section under “Promo materials”¹.

2.4 Media

Media-based communication continues to be a central component of the iPROLEPSIS dissemination strategy. Through a combination of digital channels and content formats, the project aims to raise awareness, share results, and engage its diverse audiences. Key media activities during the reporting period include the consortium maintained active communication through the project website, social media platforms, quarterly newsletters (via email and

¹ iPROLEPSIS promo materials <https://www.iprolepsis.eu/promo-materials>

LinkedIn), and one appearance in a podcast targeted at EU-level audiences. These activities together help ensure continued visibility and encourage stakeholder engagement.

2.4.1 Website

The iPROLEPSIS website² remains the main platform for sharing project updates, results, and dissemination materials with external stakeholders. Since the major upgrade completed in M6, the website has expanded to include new sections such as the Learning Hub, Deliverables, Publications, and Apps for Download (**Figure 1**). These additions enhance the presentation of project outputs and improve the user experience through clearer structure and updated content organisation.



Figure 1 Updated website with new sections – Learning Hub, Deliverables, Publications and Apps for Download

The Learning Hub is currently undergoing further development to improve usability and support integration with the miPROLEPSIS applications. The English version is scheduled for completion by the end of July 2025. As with the remaining sections of the website, the Learning Hub will be available in four languages – English, Portuguese, Greek and Dutch – and will feature an updated visual design, a News Feed section, and interactive Quizzes to enrich the educational experience.

Throughout the M19–M32 period, the website has been regularly updated with news, event highlights, and new resources, maintaining the average of two posts per month. Translation of the website's main pages into Dutch³, Portuguese⁴, and Greek⁵ – initiated earlier in the project – have supported a broader multilingual reach. Although these efforts were also reported in D6.3 and D6.8, the updates remain relevant in this reporting period, as they continue to enhance accessibility for diverse audiences.

² iPROLEPSIS website <https://www.iprolepsis.eu/>

³ iPROLEPSIS website in Dutch, <https://www.iprolepsis.eu/nl>

⁴ iPROLEPSIS website in Portuguese, <https://www.iprolepsis.eu/pt>

⁵ iPROLEPSIS website in Greek, <https://www.iprolepsis.eu/el>

Despite these efforts, website traffic remains below the KPI target of 1,000 visitors per month, averaging 177 monthly visitors between June 2023 and August 2025 (**Figure 2**). One factor contributing to limited traffic monitoring is the cookie consent policy of the Wix platform, which restricts full tracking when users decline cookies.




Figure 2 Website page views 2023 06 01 – 2025 07 01

To support compliance and transparency, the website's Privacy and Cookies Policy⁶ was updated in May 2025 in line with GDPR requirements.

The website will continue to serve as a key channel for publishing project outcomes and engaging stakeholders as iPROLEPSIS progresses toward its final phase.

2.4.2 Social media

Social media remains a key communication tool for iPROLEPSIS, supporting visibility, stakeholder engagement, and the dissemination of project results. The project maintains an active presence across six platforms: LinkedIn, X, Facebook, Instagram, YouTube, and more recently, Bluesky.

These channels are used to share project updates, results, event announcements, and educational content with a broad and diverse audience. During this reporting period, Bluesky was introduced in response to changes on X, helping ensure continued engagement, particularly with healthcare professionals and digital health communities.

All accounts follow the project's visual identity guidelines and are linked through the iPROLEPSIS website. Posting frequency remains steady, with at least two updates per month across the main platforms.

Table 1 Social media channels

Social media channel	Handle in the channel	Reference
LinkedIn	@iProlepsis	https://www.linkedin.com/company/iprolepsis/

⁶ Website Privacy and Cookies policy <https://www.iprolepsis.eu/privacy-policy>

Social media channel	Handle in the channel	Reference
X	@iproleipsis	iPROLEPSIS (@iproleipsis) / X (twitter.com)
Facebook	@iPROLEPSIS	https://www.facebook.com/iPROLEPSIS
YouTube	@iPROLEPSIS	iPROLEPSIS - YouTube
Instagram	@iproleipsis	https://www.instagram.com/iproleipsis/
Bluesky	@iproleipsis.bsky.social	https://bsky.app/profile/iproleipsis.bsky.social

To date, iPROLEPSIS has 838 followers across all social media accounts (




Figure 3), reflecting a 29% increase since M18.




Figure 3 iPROLEPSIS number of followers on social media channels

2.4.2.1 LinkedIn

As of M31, LinkedIn has remained the most active social media channel for iPROLEPSIS. It serves as a key platform for engaging with professional audiences and sharing updates on project milestones, events, and publications. The LinkedIn page currently has 519 followers, reflecting a 39% increase since M18 (**Figure 4**).




Figure 4 iPROLEPSIS LinkedIn profile and followers demographics

The majority of iPROLEPSIS LinkedIn followers come from academic and research sectors, with the top industries being Higher Education (15.9%), Research Services (9.9%), and IT Consulting (8.5%). This reflects the project's strong alignment with scientific and technical communities. Geographically, most followers are based in Greece – particularly Thessaloniki (13.6%) and Athens (11.3%) – followed by locations in Portugal, the Netherlands, Germany, and other EU countries, consistent with the consortium's outreach footprint. (**Figure 4**).

To maintain engagement, at least two posts are published each month. Content typically includes project updates, participation in events, awareness campaigns, highlights of project milestones and achievements, and news from consortium partners (**Figure 5**).




Figure 5 iPROLEPSIS presence LinkedIn

With steady growth and consistent interaction, LinkedIn remains a main channel for maintaining professional engagement and sharing project progress with relevant stakeholders.

2.4.2.2 Instagram

The iPROLEPSIS Instagram account was launched in M15 to support outreach through visual content and connect with broader audiences. (Figure 6).




Figure 6 iPROLEPSIS Instagram profile

Since M18, the number of followers has grown from 19 to 111 by M31, increasing more than five times. This makes Instagram the fastest growing iPROLEPSIS social media account during the reporting period.

Instagram is used to share visual highlights of project activities, including reels and posts. Content typically covers events, achievements, and news from the project. Although similar in scope to updates on other platforms, the use of visual formats supports accessibility and visibility among wider audiences.

2.4.2.3 X

The iPROLEPSIS X account has been used for real-time updates, event announcements, and visibility efforts targeting the broader research and digital health space (Figure 7).




Figure 7 iPROLEPSIS X profile

Between M24 and M26, the number of followers on X dropped sharply from 306 to 116 – a 62% decrease. This decline is attributed to platform-wide changes, such as algorithm updates and the removal of inactive or spam accounts, which impacted engagement across many users and projects. A slight recovery followed, with follower numbers increasing to 126 by M31. These fluctuations reflect broader platform dynamics and were also noted in the previous report (D6.8).

Despite the reduced follower count, the account remains active for sharing project milestones and supporting ongoing dissemination efforts.

In addition, the iPROLEPSIS recently joined three targeted Communities on X – *Twitter Health*, *Health Tech / Digital Health* and *AI in Healthcare* – with over 15K, 4.3K and 3.4K members respectively. These groups offer opportunities for thematic outreach, and future posts are planned to increase interaction with digital health professionals and related audiences (Figure 8). These Communities are expected to support increased visibility and more targeted engagement in the coming period.



Figure 8 X Communities joined by iPROLEPSIS for thematic digital health engagement

The X platform continues to serve as a relevant channel for outreach and thematic communication activities.

2.4.2.4 Facebook

The iPROLEPSIS Facebook page continues to serve as a supplementary platform to reach broader and less specialised audiences, particularly general public (Figure 9). The page is used to share project updates, photos, and event highlights in an accessible format.




Figure 9 iPROLEPSIS Facebook profile

As of M31, the page has 43 followers, showing a modest increase of 10% since M18. As previously reported, engagement on Facebook remains limited for most EU R&I projects, reflecting the platform's evolving user base and content preferences. A Psoriatic Arthritis support group previously joined to support outreach (as reported in D6.3) no longer appears to be active.

Facebook remains a secondary but supportive channel in the project's overall communication strategy, particularly for informal and visual content.

2.4.2.5 Bluesky

Bluesky was introduced as a new channel for iPROLEPSIS in M27, following reduced engagement on X caused by platform changes and the removal of inactive accounts. The aim was to explore alternative spaces for reaching health professionals and maintaining digital visibility (Figure 10).




Figure 10 iPROLEPSIS Bluesky profile

As of M31, the iPROLEPSIS Bluesky account has 27 followers, up from 4 in M28. Bluesky remains experimental in scope and reach, but it is monitored as an additional space for targeted communication.

2.4.2.6 YouTube

The iPROLEPSIS YouTube channel was launched in M13 to support visual storytelling and share video content related to project activities (**Figure 11**). As of M30, the channel has 12 subscribers and includes 10 videos and 3 short videos – up from 5 videos reported in the previous period (D6.3). The content covers topics such as interviews with project partners and awareness initiatives.




Figure 11 iPROLEPSIS YouTube profile

YouTube remains a complementary platform within the broader media strategy and is primarily used for hosting and sharing audiovisual materials via the website and social media.

2.4.3 Partners involvement in online visibility

Consortium partners continue to contribute to the project's online visibility through their institutional and professional communication channels. These efforts include sharing iPROLEPSIS updates on websites, social media, and newsletters, as well as highlighting project participation in events and publications.

During the current reporting period, partners supported communication activities by posting visual content, referencing project milestones, and disseminating relevant outputs across various platforms. These decentralised actions help extend the project's reach, reinforce its identity, and promote engagement across diverse stakeholder groups. (**Figure 12**).

These efforts support broader outreach, help reinforce project branding, and strengthen the visibility of iPROLEPSIS across different stakeholder networks and professional communities.

2.4.4 Newsletter

The iPROLEPSIS newsletter⁷ continues to serve as a regular communication tool to keep stakeholders informed about project progress, events, and key highlights. Issued quarterly since M3, five newsletters were released during the current reporting period (M19–M32), bringing the total to nine (**Figure 13**).

⁷ iPROLEPSIS Newsletter <https://www.iprolepsis.eu/newsletter>




Figure 12 Examples of iPROLEPSIS partner's dissemination activities on social media



Figure 13 iPROLEPSIS Newsletters

The content is tailored to suit different audiences, using clear, reader-friendly language, and includes news updates, event recaps, interviews, publications and other relevant project developments. Newsletters are distributed via Wix Email marketing, promoted on social media, and made available for download on the project website. They are also shared on the

Zenodo OpenAIRE repository⁸ to support broader dissemination and Open Science access (Figure 14).




Figure 14 iPROLEPSIS Newsletter on Zenodo

To expand reach, the project continues to issue a LinkedIn newsletter⁹, introduced in M15. As of M30, the newsletter has 267 subscribers on LinkedIn and 88 through the website, bringing the total to 355 subscribers. This reflects a 41% increase compared to the previous period reported in D6.3, when total subscribers reached 251 (191 via LinkedIn, 60 via website).

Additionally, newsletters uploaded to Zenodo have accumulated 196 views and 163 downloads to date, supporting visibility through open-access platforms.

Together, these efforts ensure continued visibility, transparency, and engagement with a growing community of stakeholders.

2.4.5 Major media

No traditional major media (TV/radio) presence was achieved up to M32. Major media engagement is planned to commence from M36 once tangible results have been produced and can be showcased.

However, during the current reporting period, iPROLEPSIS explored alternative broadcast formats. In M27, the project was featured in an episode of the Digital Rheumatology Network Podcast on Spotify¹⁰. In this interview, Patty de Groot (EMC) discussed the role of digital biomarkers in rheumatology care, explaining how iPROLEPSIS supports early diagnosis and personalised treatment pathways (Figure 15).

⁸ Zenodo OpenAIRE

https://zenodo.org/me/uploads?q=&f=shared_with_me%3Afalse&l=list&p=1&s=10&sort=newest

⁹ iPROLEPSIS LinkedIn newsletter, <https://www.linkedin.com/newsletters/iprolepsis-7173598016707235840/>

¹⁰ Digital Rheumatology Network Podcast, <https://open.spotify.com/episode/6MFmz5GtcP4oau2kAWGF3N>




Figure 15 Digital Rheumatology Network Podcast on Spotify

This podcast appearance marks an important step in broadening the project's communication efforts through audio-based media and supports the overall dissemination strategy by reaching new stakeholder audiences.

2.5 Publications

During the reporting period (M19–M32), the iPROLEPSIS project produced 9 scientific publications, demonstrating continued progress in disseminating project results through academic and research communities. These publications cover core innovations of the project, including serious games for PsA, digital biomarkers, and AI-driven healthcare solutions.

The following publications were produced between M19–M32:

1. Hadjileontiadis, L. J., et al. (2025, June). European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis. *eClinicalMedicine, The Lancet*¹¹.
2. Ramalho, B., et al. (2024, June). Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes. In *Proceedings of the 17th International Conference on Pervasive Technologies Related to Assistive Environments* (pp. 569–575)¹².
3. Ramalho, B., et al. (2024, June). “The Kite” Breathing Serious Game: Agile Co-Design for Psoriatic Arthritis. In *2024 IEEE 22nd Mediterranean Electrotechnical Conference (MELECON)* (pp. 1036–1041). IEEE¹³.
4. Papastratis, I., et al. (2024). Can ChatGPT provide appropriate meal plans for NCD patients? *Nutrition*, 21, 12291¹⁴.
5. Papastratis, I., et al. (2024). AI nutrition recommendation using a deep generative model and ChatGPT. *Scientific Reports*, 14(1), 14620¹⁵.
6. Tsiantis, V., et al. (2024, June). ChatGPT in Nutrition: Trends, Challenges, and Future Directions. In *Proceedings of the 17th International Conference on Pervasive Technologies Related to Assistive Environments* (pp. 548–553)¹⁶.
7. Ramalho, B., et al. (2024). Developing Sensorimotor Art Games for Psoriatic Arthritis using Agile Storyboarding and Game Co-Design Processes. *DSAI 2024*¹⁷.

¹¹ [https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370\(25\)00175-0/fulltext](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00175-0/fulltext)

¹² <https://dl.acm.org/doi/10.1145/3652037.3663939>

¹³ <https://ieeexplore.ieee.org/document/10608739>

¹⁴ <https://ieeexplore.ieee.org/document/10608739>

¹⁵ <https://www.nature.com/articles/s41598-024-65438-x#Ack1>

¹⁶ <https://dl.acm.org/doi/10.1145/3652037.3663898>

¹⁷ <https://zenodo.org/records/13142606>

8. Vivekanantham, A., et al. (2024). Proceedings of the 7th IFPA WPPA Conference: Hot topic debate: preventing psoriatic arthritis in patients with psoriasis. Proceedings of the 7th IFPA-WPPAC¹⁸.
9. de Groot, P., et al. (2024). Digital biomarkers for psoriatic arthritis: a qualitative focus group study on patient-perceived opportunities and barriers. RMD Open, 10:e004699¹⁹.

As of M32, iPROLEPSIS has produced a total of 10 scientific publications, including one reported in D6.3, of which 5 have been published in peer-reviewed journals. These efforts contribute toward the project's target of 20 peer-reviewed publications.

All published scientific publications are also available via Zenodo repository²⁰, supporting open access and increasing the discoverability of project results.

In addition to the above, the following publications are planned or under review:

1. Determinants of Patient's Intention to Use Serious Games in Psoriatic Arthritis: A Partial Least Squares Structural Equation Modelling Approach (planned for submission to The Lancet Digital Health).
2. Digital Phenotyping: Opportunities and Challenges in Psoriatic Arthritis (journal to be determined).
3. Dynamic Difficulty Adjustment in Serious Games for Psoriatic Arthritis: A Reinforcement Learning-Based Model (planned submission to IEEE Journal of Biomedical and Health Informatics).
4. Co-designing Mobile Serious Games to Support Psoriatic Arthritis Patients with Chronic Pain (JMIR Serious Games, under review).
5. Designing The Spy and Zen Forest, Two Full-Body Exergames for Psoriatic Arthritis (submitted to IEEE International Conference on E-health Networking, Application & Services - Healthcom 2025 conference).
6. Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs (submitted to IEEE International Conference on E-health Networking, Application & Services - Healthcom 2025 conference).

The publication pipeline remains active, with several manuscripts in progress or under review, reflecting the consortium's ongoing efforts to disseminate research findings and contribute to the evolving scientific landscape in digital health and PsA.

2.5.2 Publications in business magazines

During the current reporting period, iPROLEPSIS began expanding its visibility beyond scientific audiences by targeting publications accessible to patient groups, industry stakeholders, and broader professional communities.

In M29, the article "AI, Apps and Arthritis: A Digital Leap in Psoriatic Care" was published by Khalifa University²¹. This piece highlights how the iPROLEPSIS project is applying artificial intelligence, mobile health tools, and real-world data to personalise and improve PsA care. It presents key project innovations – such as explainable AI, the miPROLEPSIS app, and gamified patient support tools – in an accessible format for healthcare professionals, digital health innovators, and the general public.

¹⁸ <https://conferences.medicom-publishers.com/proceedings/proceedings-in-dermatology/7th-ifpa-wppac/preventing-psoriatic-arthritis-in-patients-with-psoriasis/>

¹⁹ <https://rmdopen.bmj.com/content/10/4/e004699>

²⁰ Zenodo, <https://zenodo.org/me/uploads?q=&l=list&p=1&s=10>

²¹ Khalifa University Research News, <https://www.ku.ac.ae/ai-apps-and-arthritis-a-digital-leap-in-psoriatic-care>

In parallel, the project reached out to patient communities. In M22, an article about iPROLEPSIS was published in Psoriasispatiënten Nederland²² Psoriasis Magazine, helping increase public and patient-facing awareness of the project's objectives and activities (**Figure 16**). This volunteer organisation advocates for over 300,000 people in the Netherlands affected by psoriasis and psoriatic arthritis. While this article is not classified as a business magazine publication, it represents an important step in reaching patient advocacy networks.



Figure 16 Article in the Psoriasispatiënten Nederland Psoriasis Magazine

These publications mark the first step towards meeting the project's KPI of producing at least four business magazine articles. Additional outreach to industry-facing publications is planned for the upcoming reporting period, aligned with the growing maturity of project results and the upcoming validation of tools in real-world settings.

2.6 Events

Events continue to be a key component of the iPROLEPSIS dissemination and communication activities. They provide opportunities to present project results, engage with stakeholders, and support collaboration across research, clinical, and industry communities. Participation in events also contributes to the project's visibility through updates on communication channels such as the website, social media, and newsletters.

During the current reporting period (M19–M32), project partners actively contributed to:

- **Scientific conferences:** Participation in 8 major conferences, including the GRAPPA Annual Meeting 2025, Health Data Summit 2025, and IEEE EMBC 2024, among others.
- **Business and industry events:** Participation in 2 events, including the HiTech Program Final Pitch and Innohealth Forum, project presented to industry players such as AbbVie, ELPEN Pharma, and Sonova International.
- **Workshops/seminars/special sessions:** Participation in 7 events such as the EIT Health Morning Health Talk, the European Researchers' Night, and workshops at the Health Data Summit 2025.
- **Clinical focus groups with patients:** Continued engagement with patients through co-creation sessions, feedback activities, and collaborative input on the development and refinement of Digital Health Tools.

Detailed descriptions of the events are presented in the following subsections: **2.6.1-2.6.4**.

²² Psoriasispatiënten Nederland, <https://psoriasispatientennederland.nl/>

2.6.1 Scientific conferences

During the current reporting period, the project has participated in eight (8) scientific conferences:

1. GRAPPA Annual Meeting 2025, 10-12 July 2025, Bogotá, Colombia
2. 7th Panhellenic Multidisciplinary Congress of Autoimmune Diseases, Rheumatology & Clinical Immunology, March 2025, Portaria, Greece
3. Health Data Summit 2025, 18-19 March 2025, Brussels, Belgium
4. DSAI – 11th International Conference on Software Development and Technologies for Enhancing Accessibility, 13-15 November 2024, Abu Dhabi, UAE
5. 2nd Healthy Longevity Symposium, 21-22 November 2024, Abu Dhabi, UAE
6. 16th Panhellenic Conference of EPEMY, 3-6 October 2024, Ioannina, Greece
7. IEEE EMBC 2024, 15-19 July 2024, Orlando, Florida, USA
8. IEEE MELECON 2024, 25-27 June 2024, Porto, Portugal

The iPROLEPSIS project was presented during the Soapbox Session at the GRAPPA Annual Meeting 2025 in Bogotá, Colombia (




Figure 17). The presentation provided an overview of the project's key objectives and emerging results focusing on how iPROLEPSIS aims to improve PsA care through digital phenotyping. The talk highlighted how digital biomarkers – captured via smartphone typing dynamics and video-based motor tasks –can support the assessment of hand function in everyday life. The session reached approximately 350 stakeholders, including clinicians, researchers, and industry representatives, helping raise awareness of iPROLEPSIS and its goals within the psoriatic disease community.




Figure 17 Grappa Annual Meeting 2025

From 28-30 March 2025, the 7th Panhellenic Multidisciplinary Congress of Autoimmune Diseases, Rheumatology & Clinical Immunology was held in Portaria, Greece. Maria Mytilinaïou (AUTH) presented an overview of the iPROLEPSIS and HIPPOCRATES projects and ongoing clinical studies. The congress brought together clinicians and researchers from across Greece, offering a valuable opportunity to share insights and strengthen collaboration.



Figure 18 The 7th Panhellenic Multidisciplinary Congress of Autoimmune Diseases, Rheumatology & Clinical Immunology

At Health Data Summit 2025 in Brussels, organised by The European Institute for Innovation Through Health Data, iPROLEPSIS was presented during two sessions: "Trustworthy AI in Digital Health: From Guidelines to Practice" and "Advanced Strategies and Tools for Ensuring

High-Quality Data During Data Mapping" (**Figure 19**). Further details from the sessions are included in **Section 2.6.3**.




Figure 19 Health Data Summit 2025

At the 2nd Healthy Longevity Symposium organised by Khalifa University in Abu Dhabi, UAE, Prof. Leontios Hadjileontiadis presented the Serious Game Suite for PsA patients (**Figure 20**). The symposium gathered leading experts to explore key topics related to longevity and aging, which is recognised as the root cause of many chronic disease. The event focused on the latest advancements in aging mechanisms, genomic precision medicine, rejuvenation, and social health policies. Discussions highlighted the potential of AI, advanced technologies, and precision medicine to address the challenges of aging, slow age-related diseases, and improve overall well-being.



Figure 20 The 2nd Healthy Longevity Symposium

Prof. Leontios Hadjileontiadis also presented the iPROLEPSIS Sensorimotor Games at the 11th International Conference on Software Development and Technologies for Enhancing Accessibility and Fighting Info-exclusion (DSAI 2024) held in Abu Dhabi, UAE (**Figure 21**).

DSAI is a leading international forum focused on accessible and usable Information and Communication Technologies (ICT). The conference provided an excellent platform to share progress on the iPROLEPSIS project and highlight its innovative approach to digital healthcare solutions.



Figure 21 The 11th International Conference on Software Development and Technologies for Enhancing Accessibility and Fighting Info-exclusion (DSAI 2024)

AUTH presented iPROLEPSIS at the 16th Panhellenic Conference of EPEMY in Ioannina, Greece. The presentation addressed important topics related to nesting, the role of enthesitis in PsA and Axial Spondyloarthritis, and the most appropriate treatment approaches for enthesitis and digitalis. This conference focused on inflammatory and autoimmune rheumatic, gastrointestinal, and skin diseases, as well as osteoporosis and osteoarthritis. Individual sessions covered Covid-19, cancer, neurological syndromes, and co-morbidities. The event emphasised clinically applied treatments, with interactive, cross-company tutorials and presentations of research projects from domestic centers, which were awarded for their contributions.

Project partner PLUX, participated in the 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), held in Orlando, Florida, USA. PLUX presented the innovative work of the iPROLEPSIS project, which focuses on developing a novel, personalised digital care ecosystem for individuals with PsA (**Figure 22**). EMBC is the world's largest international biomedical engineering conference, featuring cutting-edge developments in translational research and healthcare technology.




Figure 22 The 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)

At IEEE MELECON 2024 in Porto, Portugal, the iPROLEPSIS Breathing Games were presented (**Figure 23**). The conference is a major international forum presenting design methodologies, techniques, and experimental results in emerging electro-technologies. It is one of the flagship conferences of the IEEE Region 8 (the largest region of IEEE including Europe, Africa, and Middle East).



Figure 23 IEEE MELECON 2024

The upcoming conferences include IEEE International Conference on E-health Networking, Application & Services - Healthcom 2025, Abu Dhabi, UAE (21-23 October 2025). The iPROLEPSIS and AI-PROGNOSIS projects will co-organise a workshop titled: “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact”.

As of M32, the iPROLEPSIS project has participated in a total of thirteen (13) scientific conferences – five reported in D6.3 and eight during the current reporting period. This reflects the project’s consistent engagement with the scientific and clinical research communities and

its commitment to high-impact dissemination in the fields of rheumatology, artificial intelligence, and digital health.

2.6.2 Business and industry events

Engagement with business stakeholders and industry platforms is a key element of the iPROLEPSIS dissemination strategy, helping bridge the gap between research outcomes and real-world application. During the current reporting period (M19–M32), the project participated in five (5) business and industry events. Additionally, two meetings from the earlier reporting period (M1–M18) are also included, as they were not previously reported in D6.3 due to limited information at the time:

1. HiTech Program Final Pitch, June 2025, Lisbon, Portugal
2. InnoHealth Forum 2024, September 2024, Thessaly, Greece
3. Meeting with Sonova International, September 2024, Greece
4. Meeting with AbbVie, September 2024, Greece
5. Meeting with AbbVie, May 2024, Greece
6. Meeting with ELPEN Pharma, December 2024, Greece
7. Meeting with the Center of Digital Innovation of Pfizer, February 2023, Greece

On June 26, 2025, iPROLEPSIS Games were presented during the final pitch session of the HiTech Program in Lisbon, Portugal (**Figure 24**). FMH/IST-ULisboa introduced the iPROLEPSIS Games to an audience of investors and stakeholders interested in supporting innovative health solutions. This opportunity marked an important step in sharing iPROLEPSIS tools with a wider innovation and investment community.



Figure 24 Final pitch session of the HiTech Program

The iPROLEPSIS project partner AINIGMA participated in the InnoHealth Forum 2024 (20-21 September 2024), an event that promotes and highlights innovative health technology solutions for the benefit of humanity. With 25 exhibitors, 50+ live demos of cutting-edge health products and services and over 130 matchmaking meeting and networking opportunities, this forum was a great opportunity to spread the word about the iPROLEPSIS project and connect with potential end-users (**Figure 25**).

In September 2024, AUTH presented the iPROLEPSIS project at a meeting with Sonova International²³. The iPROLEPSIS concept and vision were shared, showcasing the innovative approaches the project is undertaking. The event featured a range of topics, including advancements in digital biomarkers, innovations in hearing instruments by Sonova Group, ear-EEG technology, auditory processing disorders, and insights into the hearing aid market in Greece.

Two meetings were held with AbbVie in 2024 to explore collaboration opportunities. In June, AUTH presented its research activities, leading to a follow-up in September focused on iPROLEPSIS work in nail condition and swollen joint detection in psoriatic arthritis.

In December 2024, AUTH held a meeting with ELPEN Pharma company to present the iPROLEPSIS project and explore potential collaboration opportunities.



Figure 25 InnoHealth Forum 2024

In February 2023, AUTH held a meeting with the Center for Digital Innovation (CDI) at Pfizer²⁴. The discussion explored early-stage synergies around digital biomarkers and AI-enabled patient monitoring.

²³ https://www.linkedin.com/posts/activity-7235938862856867840-ij8b?utm_source=share&utm_medium=member_desktop

²⁴ CDI's new collaboration with the Aristotle University of Thessaloniki puts patients at the forefront of the design of digital applications for Health | Pfizer's Center for Digital Innovation

In total, iPROLEPSIS has engaged in ten (10) business and industry events: three reported in D6.3 and seven in this report, reflecting ongoing efforts to build industry connections and promote project uptake.

2.6.3 Workshops, seminars and special sessions

During the current reporting period, the project was presented in 7 (seven) workshops, seminars, and special sessions.

In June 2025, the iPROLEPSIS project was presented at the 1st Morning Health Talk – Greece, part of the EIT Health Morning Health Talks series (**Figure 26**). The event, titled “Co-Creating Health Innovation Ecosystems: Empowering Providers and Citizens Beyond Financial Incentives”, was organised by EIT Health Greece. AUTH presented an overview of iPROLEPSIS, developing a novel personalised digital care ecosystem for people with (PsA).

The session brought together a diverse group of participants, including:

- EIT and EIT Health Greece representatives
- European Digital Innovation Hubs – Health Hub
- European Network of Living Labs
- Digital health consultants from the Greek Ministry of Digital Governance
- Public and private hospitals
- Private health insurance companies, homecare providers, and telemedicine companies



Figure 26 The 1st Morning Health Talk – Greece

The event offered valuable opportunities for sharing perspectives, building connections, and exploring collaborative strategies for the future of healthcare innovation.

In March 2025, at the Health Data Summit 2025 in Brussels, organised by The European Institute for Innovation Through Health Data, iPROLEPSIS was presented in two sessions (**Figure 27**):

- AUTH presented iPROLEPSIS during the session “Trustworthy AI in Digital Health: From Guidelines to Practice”. The presentation outlined the methodology used in iPROLEPSIS to develop a trustworthy AI (TAI) framework tailored to the project’s specific needs. A case study on the Lifestyle Recommendation Engine demonstrated how it aligns with TAI principles and recommendations.
- AINIGMA presented the project during the session “Advanced Strategies and Tools for Ensuring High-Quality Data During Data Mapping”. The presentation focused on how

iPROLEPSIS uses the OMOP Common Data Model (CDM) and OHDSI tools to harmonize health datasets from various sources.



Figure 27 Workshops at Health Data Summit 2025

In November 2024, FMH/IST-ULisboa presented the iPROLEPSIS Games during the Pitch Competition at the PhD Open Days event at the Técnico Innovation Center, highlighting the role of serious games in the iPROLEPSIS project (**Figure 28**).



Figure 28 The Pitch Competition during the PhD Open Days

Also in November 2024, iPROLEPSIS ongoing research was represented by Erasmus MC (EMC) at the World Psoriasis Day Patient Event in Nijkerk, the Netherlands (**Figure 29**). With over 90 participants, the event facilitated dialogue between patients, researchers, and clinicians on psoriatic disease care and innovation.



Figure 29 Informative event for World Psoriasis Day 2024 in Nijkerk (the Netherlands)

In September 2024, FMH/IST-ULisboa presented the iPROLEPSIS Games and the iPROLEPSIS project during the European Researchers' Night in Oeiras, Portugal (**Figure 30**). This event, part of the "Science for Everyone (SCIEVER) – Inclusion and Sustainability" initiative, aimed to engage the public with scientific advancements. Researchers from various fields participated, sharing their work through interactive presentations, live demonstrations, and diverse activities, fostering a stronger connection between science and the community.



Figure 30 The European Researchers' Night

In July 2024, the HUMAN Lab meetup was organised by Universidade de Lisboa (Instituto Superior Técnico, IST). FMH/IST-ULisboa presented the iPROLEPSIS project and the iPROLEPSIS Games (**Figure 31**). The presentation also covered the project's main goals, motivations, and key milestones.



Figure 31 The HUMAN Lab meetup

iPROLEPSIS and AI-PROGNOSIS will co-organise a full-day workshop titled “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact” as part of IEEE HealthCom 2025 (21–23 October 2025, Abu Dhabi). This workshop aims to bring together researchers, clinicians, engineers, data scientists, digital health innovators, and policymakers to share advancements and challenges in AI-enabled health solutions for Non communicable diseases (NCDs).

Up to date, nine (9) workshops, seminars, and special sessions have been delivered – two reported in D6.3 and seven during the current period – demonstrating sustained multi-stakeholder engagement and outreach.

2.6.4 Clinical focus groups with patients

This section provides a short overview of patient-involved activities conducted throughout the project. These include clinical focus groups, interviews, co-creation sessions, usability testing, and survey participation – all of which supported the co-design and validation of the iPROLEPSIS Digital Health Tools (DHTs).

Patient involvement has been central to ensuring the usability, relevance, and acceptability of the tools. These structured activities informed the development of user scenarios, usability refinements, and user requirements across the different DHT components. By M31, a total of 33 patient-involved activities were conducted, comprising 11 focus groups and interviews and 22 tool-specific co-creation sessions (

Table 2).

Table 2 Number of interactions with patients

Activity	Number of interactions
Focus Groups / Interviews	11
miPROLEPSIS app (study version / BiAURA / Recommendations)	9 / 2 / 2
Personalised Gaming Suite	7
miPROLEPSIS Dashboard	2
Total number of interactions	33

In total, 469 patients were involved in various stages of the user research and co-creation process (**Table 3**). These included individuals participating in qualitative formats such as focus groups and co-design sessions, as well as respondents to the online survey and usability testing.

In addition, 246 patients were recruited for the PDPID study, who will provide structured feedback through usability questionnaires. Their input will further inform the evaluation of usability, content relevance, and overall patient experience during real-world use.

Table 3 Patient participation by format

Format	Patients
Focus Groups	39
Survey	398
Usability Testing	16
Interactions	16
PDPID Study Participants	246
Total number of stakeholders involved	469 (excluding PDPID study)

All these activities provide essential insights into patients' needs, preferences, and expectations, directly contributing to the functional and design decisions across DHTs. A comprehensive overview of user research and co-creation activities will be provided in the D2.5, Updated Report on User Research and Co-Creation Process.

2.7 Communication material

The iPROLEPSIS communication kit²⁵ – including poster, flyer and roll-up poster – ensures consistent, professional, and recognisable communication across all channels. While no major refinements have been made since the initial development, the existing materials continue to support project visibility and outreach during conferences, public events, and stakeholder engagement activities (**Figure 32**).

²⁵ iPROLEPSIS Communication kit, <https://www.iprolepsis.eu/promo-materials>



Figure 32 iPROLEPSIS flyer, poster and roll-up displayed at events

2.8 PsA educational material

Since D6.3, iPROLEPSIS has made steady progress in the development and dissemination of educational resources aimed at supporting individuals living with PsA, their families and caregivers. These materials were designed to improve health literacy, promote self-management, and provide accessible, evidence-based information on PsA symptoms, treatments, and lifestyle strategies.

Key developments to date include:

- **Finalisation of the Patient Handbook and Infographics**
 - The English version of the Psoriatic Arthritis Patient Handbook and the full set of 18 educational infographics have been finalised and published on the project website²⁶.
 - Translations into Dutch, Greek, and Portuguese were completed during the reporting period and will be made publicly available once the Learning Hub's upgraded section is launched.
 - The handbook covers a wide range of topics, including PsA causes, symptoms, diagnosis, and drug treatments, along with non-pharmacological interventions such as diet, physical therapy, and occupational therapy. Additional sections address PsA's impact on work, sleep, fatigue, emotional well-being, relationships, fertility, and pregnancy.
- **Learning Hub – ongoing upgrade**

²⁶ iPROLEPSIS Learning Hub, <https://www.iprolepsis.eu/learning-hub>

The Learning Hub is currently undergoing an upgrade to ensure full integration with the miPROLEPSIS mobile application (**Figure 33**). The redesigned interface will offer a user-friendly layout with thematic tiles:

- *Psoriatic Arthritis Key Facts* – a dedicated section for the infographic series
- *Psoriatic Arthritis Handbook* – online access to the full handbook
- *News Feed* – a live RSS²⁷ feed displaying recent articles from sources such as [Nature Reviews Rheumatology](#), [MedlinePlus](#), [Journal of Psoriatic Arthritis \(SAGE\)](#) and [Psound Bytes™](#)
- *Quizzes* – designed to reinforce key concepts and support active learning, helping users consolidate knowledge, assess their understanding, and revisit topics as needed
- *Search* – a function to help users easily browse content.




Figure 33 Preview of the upgraded Learning Hub page on the iPROLEPSIS website

Once launched, the new Learning Hub is expected to significantly enhance accessibility, usability, and patient engagement.

- **Digital integration**

- The educational materials, already accessible via the iPROLEPSIS website, are being prepared for integration into the miPROLEPSIS mobile application, enabling users to navigate the handbook and infographics directly through the app interface.

- **Multimedia promotion**

- To increase awareness and visibility, a series of short video clips highlighting key sections of the Patient Handbook have been shared on social media platforms, including YouTube^{28, 29} and LinkedIn³⁰.

²⁷ RSS feed, <https://en.wikipedia.org/wiki/RSS>

²⁸ <https://www.youtube.com/shorts/j7WWC31FQEk>

²⁹ <https://www.youtube.com/shorts/Nc1AgIRtSN4>

³⁰ <https://www.linkedin.com/feed/update/urn:li:activity:7292820376043032577>

As of M32, iPROLEPSIS has established a solid base of multilingual, user-friendly educational materials. With the Learning Hub upgrade in progress, the project is taking steps to improve the accessibility and visibility of its PsA-related resources.

2.9 Clustering and networking activities

During the reporting period (M19-M32), iPROLEPSIS took part in several clustering and networking activities with other EU-funded projects and initiatives. These efforts aim to support knowledge exchange, joint dissemination, and collaboration on common research goals in digital health and AI for healthcare.

2.9.1 Booster service delivery

To support its dissemination and exploitation, iPROLEPSIS continued its engagement with Booster initiative, following its initial application for Horizon Results Booster (HRB)³¹ Modules A and C in M16.

More specifically, within the scope of **Service 3.2: Portfolio Analysis (POA)**, between December 2024 and June 2025, the project participated in a total of four meetings with Booster experts:

- 5 December 2024 – Entry-Level Consultation Call #1: Introduction to Booster services, identification of key exploitable results (KERs), and review of the dissemination and exploitation ecosystem.
- 8 January 2025 – Entry-Level Consultation Call #2: Completion of the Readiness Assessment and development of a tailored Service Roadmap for the next phases.
- 27 March 2025 – Portfolio Analysis Introductory Call: Alignment on clustering objectives, including the shared use of real-world data and AI in healthcare; a stakeholder mapping exercise identified key groups such as policymakers, healthcare providers, research institutions, and digital health SMEs as common engagement targets.
- 5 June 2025 – Convergence Call: Review of the clustering calendar, agreement on joint KERs, and planning of upcoming dissemination actions.

Building on needs identified in Service 1.1 and other building block services, the POA aimed to support the creation of a portfolio of results collected from like-minded sister projects suitable for joint dissemination and exploitation activities. This approach fosters sustainability of project outcomes through networking, clustering, and knowledge exchange.

As a result, iPROLEPSIS established a cluster with two other EU-funded projects: AI-PROGNOSIS³² and REBECCA³³. The current activities focus on joint dissemination of a thematic cluster centered on AI-driven digital health solutions and real-world evidence for personalized care – specifically AI-enabled tools addressing chronic conditions such as psoriatic arthritis, Parkinson's disease, and breast cancer survivorship.

As a result of these sessions, the following key actions and deliverables were achieved:

- **Joint KER identification:**
 - Real world data collection and analysis platforms
 - AI-based digital health decision support & monitoring tools
- **Creation of shared communication materials**, including:
 - A joint news release

³¹ Horizon Result Booster, <https://www.horizonresultsbooster.eu/>

³² AI-PROGNOSIS, <https://www.ai-prognosis.eu/>

³³ REBECCA, <https://rebeccaproject.eu/>

- A shared PowerPoint presentation template
- A cluster identity text for use across project websites
- Social media templates via Canva
- A clustering calendar with proposed event and content planning
- **Proposed joint dissemination opportunities at:**
 - Future of Health Europe 2025 (30 September – 1 October 2025, London, UK)
 - AI Health Summit – Economist Impact (26–27 November 2025, London, UK)

These recommendations are included in the Final Report provided by Booster experts. Follow-up cluster meetings will follow to discuss possible joint participation and coordination.

To support cluster visibility, a dedicated article³⁴ was published on the iPROLEPSIS website, outlining the background, shared goals, and future plans of the collaboration with AI-PROGNOSIS and REBECCA. In parallel, a coordinated social media campaign was carried out, during which all three projects shared dedicated posts across their platforms to introduce and promote the cluster (**Figure 34**).




Figure 34 Social media campaign introducing the cluster

Following Service 3.2, in July 2025, iPROLEPSIS officially initiated Service 2.1 (Dissemination Support) and Service 3.1 (Networking) exclusively for the project. Additionally, Booster Service 3.5 (Audiovisual Support) is proposed for delivery in September 2025, based on

³⁴ iPROLEPSIS, AI-PROGNOSIS & REBECCA: A Thematic Cluster on AI-Driven Digital Health
<https://www.iprolepsis.eu/news/iprolepsis%2C-ai-prognosis-%26-rebecca%3A-a-thematic-cluster-on-ai-driven-digital-health>

interest expressed by the project group during the Portfolio Analysis phase. Further details will be provided in upcoming deliverables.

By taking part in the Booster services and leading the formation of a collaborative cluster, iPROLEPSIS is actively working to strengthen its visibility, align its dissemination efforts with similar EU projects, and lay the foundation for ongoing cooperation in digital health innovation.

2.9.2 Collaboration with EU initiatives and networking activities

Beyond the Booster-supported cluster, iPROLEPSIS has engaged in a range of EU-level networking and collaboration activities to foster cross-project learning, joint dissemination, and stakeholder engagement.

Key activities include:

- **Participation in AI-PROGNOSIS Plenary Meetings:**
 - 4th Plenary Meeting, 10–11 December 2024, Dresden, Germany
 - 5th Plenary Meeting, 19–20 May 2025, Thessaloniki, Greece

These meetings strengthened collaboration between the two projects, particularly in the area of AI-driven digital health solutions.

- **COMFORT-EU Project Meeting**

On 15–16 May 2025, AUTH presented the iPROLEPSIS project at the 2nd Plenary Meeting of the COMFORT-EU project³⁵, introducing the project's approach to Trustworthy AI in healthcare (**Figure 35**).




Figure 35 iPROLEPSIS presented at the COMFORT-EU project plenary meeting

³⁵ <https://www.comfort-ai.eu/news/hands-on-workshops-vibrant-discussions-on-ai-models-and-exchange-with-related-projects-the-comfort-consortium-convenes-in-thessaloniki-for-the-second-progress-meeting>

- **Health Data Summit 2025**

During the Health Data Summit (18–19 March 2025, Brussels), Dr. Charisis presented iPROLEPSIS in the session titled “Trustworthy AI in Digital Health: From Guidelines to Practice.” The session included presentations from other Horizon Europe projects such as AI-PROGNOSIS, TRUSTroke³⁶, and STRATIFYHF³⁷, with a shared focus on ethical AI integration in clinical environments.

- **Clustering Meeting with RAISE Project**

On 3 December 2024, AUTH participated in a clustering meeting with the RAISE project³⁸ in Greece to explore potential synergies and future collaboration.

- **Meeting with Greek Patients’ Association**

A virtual networking meeting with the Greek Patients’ Association³⁹ took place on 11 November 2024, supporting patient involvement and stakeholder engagement.

- **Stay Healthy Cluster Annual Meeting**

iPROLEPSIS took part in the Stay Healthy Cluster's first yearly online meeting, hosted by the IMMEDIATE project in January 2025, as part of wider efforts to align with other digital health initiatives.

Upcoming Workshop at IEEE HealthCom 2025

As a next step, iPROLEPSIS and AI-PROGNOSIS are co-organising a full-day workshop titled: “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact,” scheduled for 21–23 October 2025 at the IEEE HealthCom 2025 conference in Abu Dhabi, UAE.

All sister projects have been invited to submit contributions. The CARE-IN-HEALTH⁴⁰ project has confirmed its interest and plans to submit a paper.

Workshop topics will cover AI-driven approaches for early detection, personalised treatment, and remote care in NCDs, with a focus on digital biomarkers, ethical and regulatory challenges, user-centred design, and the translation of research into scalable digital health solutions.

These activities demonstrate iPROLEPSIS’ commitment to building cross-sector collaboration, aligning with broader EU digital health priorities, and contributing to the development of responsible and scalable AI health technologies.

3 Communication and dissemination KPIs

This section presents an updated overview of the communication and dissemination KPIs for the full period from M1 to M32, building on the baseline established in D6.3 (M1–M18) and integrating progress achieved during the current reporting period (M19–M32). The cumulative results reflect the project's ongoing efforts to promote visibility, engage stakeholders, and

³⁶ <https://trustroke.eu/>

³⁷ <https://stratifyhf.eu/>

³⁸ <https://raise-science.eu/>

³⁹ <https://greekpatient.gr/en/>

⁴⁰ <https://www.care-in-health.eu/>

disseminate results effectively across multiple channels. **Table 4** below outlines the target and reached KPIs for each activity category.

Table 4 Target and reached KPIs for M1-M18

D&C actions	What	When	Target KPIs	Reached KPIs (M1-M18)	Reached KPIs (M19-M32)	Cumulative KPIs (M1-M32)
Publications	Peer-reviewed journals	From M18, when solid scientific results are available	20 publications	1 publication (peer-reviewed)	9 publications (4 peer-reviewed)	10 (5 peer-reviewed)
	Business Magazines		4 publications	0	1 article in Khalifa University Research News; 1 article in Psoriasispatienten Nederland Psoriasis Magazine	2
Event participation	Scientific conference presentations/posters	From M12, when initial scientific results are available	20 presentations/posters	5 conferences	8 conferences	13 conferences
	Business/Industry events and EXPOs stands/booths		3 events	3 ~50 attendees	7 events ~200 attendees	10 events ~250 attendees
	Workshops/Special sessions/Seminars	From M18, when solid scientific results are available	8 events 50 expected attendees	2 events ~50 attendees	7 events ~170 attendees	9 events ~220 attendees
	Clinical focus groups with patients	From M14, when the study applications are available	6 focus groups	9 focus groups, 1 one-on-one interview	2 focus groups; 22 co-creation interactions	33 patient-involved sessions (11 focus groups/interviews + 22 co-creation sessions)
Media presence	Newsletters	From M3 every three months	1000 subscribers	4 newsletters; 251 subscribers	5 newsletters; 355 subscribers; 196 views / 163 downloads on Zenodo	9 newsletters 355 subscribers; 189 views / 163 downloads on Zenodo

D&C actions	What	When	Target KPIs	Reached KPIs (M1-M18)	Reached KPIs (M19-M32)	Cumulative KPIs (M1-M32)
	Website/blog posts	From M1	2 posts/month 1000 visitors/month	Av. 2 posts per month; Av. 182 visitors/month	Av. 2 posts per month; Av. 170 visitors/month	Av. 2 posts per month; Av. 177 visitors/month
	Social media posts	From M1	2 posts/month 2000 followers	Av. 2 post/month 649 followers	Av. 2 post/month 838 followers	Av. 2 post/month 838 followers
	Major media (TV/radio) presence	From M36, when tangible results are produced	5 presences in national media	0	0	0
			2 presences in EU-level media	0	1 Digital Rheumatology Network podcast on Spotify	1 EU-level media appearance
Networking and clustering events			≥4 networking/joint initiatives	1 joint social media campaign with sister projects	Formal cluster with AI-PROGNOSIS and REBECCA via Booster • 4 Booster meetings • 6 networking and collaboration meetings with EU-level projects and stakeholders • 1 joint session at Health Data Summit 2025 1 joint social media campaign	• 1 joint session at Health Data Summit 2025 • 6 networking and collaboration meetings with EU-level projects and stakeholders • 1 formal cluster via Booster / 4 online cluster meetings • 2 joint social media campaigns

Over M1-M32, the iPROLEPSIS project has demonstrated steady and measurable progress toward achieving its communication and dissemination objectives. During this period, the project produced 10 scientific publications, including 5 peer-reviewed papers, with additional manuscripts currently under development. Dissemination efforts included participation in 13 scientific conferences and 9 workshops or special sessions, supporting the visibility of project findings across relevant research communities.

Stakeholder engagement was further strengthened through involvement in 10 business and industry events. In terms of patient engagement, the project exceeded its original KPI of 6 clinical focus groups. By M32, a total of 33 patient-involved sessions were conducted, comprising 11 focus groups and interviews, and 22 tool-specific co-creation activities. These interactions directly contributed to the development, testing, and iterative refinement of the Digital Health Tools, ensuring that patient needs and preferences were embedded in the design process.

Clustering and networking goals were also met. The project established a formal Booster-supported cluster with sister projects AI-PROGNOSIS and REBECCA, participated in seven cross-project networking meetings, and coordinated joint dissemination activities such as a joint session at the Health Data Summit 2025 and an planned workshop at IEEE HealthCom 2025.

Progress was also evident in media engagement. Social media followers increased from 649 (M18) to 838 (M32), supported by regular posting. Newsletter subscriptions rose from 251 to 355, and dissemination through Zenodo enhanced visibility, with measurable views and downloads.

Although average website traffic remained below the long-term KPI of 1,000 monthly visitors, visits were stable between 174–182 per month. The ongoing enhancement of the Learning Hub and its planned integration with the miPROLEPSIS mobile application are expected to support increased visibility and engagement in the next phase.

For future reporting, deliverable D6.6, “Final report on project visibility and educational material”, is planned for M48.

4 Conclusions

This second report on project visibility and educational material, D6.5, presents the progress achieved by the iPROLEPSIS consortium in the areas of communication, dissemination, educational content development, and networking activities during the M19–M32 period. It builds upon the foundations laid in the first reporting phase (M1–M18) and reflects the project's ongoing efforts to increase visibility and stakeholder engagement.

Key developments include:

- **Dissemination and communication progress:** Project communication remained active across multiple channels, including the website, social media, newsletters, and participation in scientific and industry events. Scientific publication output has increased to ten publications, five of which are peer-reviewed, with further manuscripts currently planned or under review. In parallel, other content – such as short videos, video interviews, and educational infographics – has been shared regularly to support outreach and engagement. While the number of monthly website visitors remains below the initial target, other metrics – including newsletter subscriptions and social media followers – have shown consistent growth.

- **Stakeholder engagement:** The project was presented in 13 scientific conferences, 10 business and industry events, and 9 workshops or special sessions. These activities enabled the team to present project outputs to various target groups, including researchers, healthcare professionals, policymakers, and patient representatives.
- **Educational content development:** The Psoriatic Arthritis Patient Handbook and the set of 18 infographics have been finalised and published in English, with translations into Dutch, Greek, and Portuguese ready for publication. A redesigned Learning Hub is under development and is expected to improve accessibility and user experience once launched. Once the upgrade is finalised, the Learning Hub will also be integrated into the miPROLEPSIS mobile application, allowing users to access the educational materials directly through the app interface.
- **Clustering and networking:** The project successfully established a cluster with AI-PROGNOSIS and REBECCA via Horizon Results Booster services and participated in joint planning and dissemination activities. In addition, iPROLEPSIS took part in several cross-project meetings and networking events, broadening its connections across the EU research and digital health landscape.
- **Monitoring of KPIs:** The use of key performance indicators continues to support progress tracking across all communication and dissemination activities. Several targets have been met or closely approached, particularly those related to scientific conference participation, business/industry events, workshops and networking initiatives. While other areas, such as newsletter subscriptions and social media reach, show continued progress, further efforts will be made to meet final targets by M48. Ongoing data collection ensures that dissemination remains aligned with the project's strategic goals.

Moving forward, the focus will remain on expanding outreach, sharing results widely, and enhancing the accessibility of educational resources. Further updates, including final outreach figures and dissemination impact, will be presented in D6.6, "Final report on project visibility and educational material", scheduled for M48.